Transgender health最新文献_第2页

Mental Health Care Utilization, Unmet Care Needs, and Barriers to Receiving Care in Adolescence Among Transgender and Nonbinary Young Adults. 跨性别和非双性恋青少年的心理健康护理利用、未满足的护理需求和接受护理的障碍

IF 1.8

Transgender health Pub Date : 2025-08-07 eCollection Date: 2025-09-01 DOI: 10.1089/trgh.2024.0140

Gina M Sequeira, Nicole F Kahn, Marlene Chamonica Hernandez, Ruby Lucas, Kacie M Kidd, Moira Kyweluk, Wanda Pratt, Dimitri Christakis, Sarah Danzo, Laura P Richardson

{"title":"Mental Health Care Utilization, Unmet Care Needs, and Barriers to Receiving Care in Adolescence Among Transgender and Nonbinary Young Adults.","authors":"Gina M Sequeira, Nicole F Kahn, Marlene Chamonica Hernandez, Ruby Lucas, Kacie M Kidd, Moira Kyweluk, Wanda Pratt, Dimitri Christakis, Sarah Danzo, Laura P Richardson","doi":"10.1089/trgh.2024.0140","DOIUrl":"10.1089/trgh.2024.0140","url":null,"abstract":"Purpose: Few studies have explored mental health needs and barriers to accessing care among transgender and nonbinary (TNB) individuals during adolescence. The purpose of this study was to explore TNB young adults' mental health care utilization, unmet care needs, and barriers to receiving care in adolescence.Methods: A 42-item cross-sectional survey was administered to TNB individuals aged 18-20 years. Chi2 and Fisher's exact tests were used to identify differences in receipt of mental health care by demographics. Post-hoc pairwise comparisons were conducted using the Bonferroni correction for multiple comparisons when indicated.Results: Of 286 participants, approximately half (42.3%) were women and 50.7% reported being \"out\" to at least one parent before the age of 18. More than half (55.2%) reported having seen a mental health provider in adolescence; however, only 10.1% indicated that they had received enough mental health support. Significant differences were found in having seen a mental health provider by gender identity (p = 0.02) and outness to parents during adolescence (p < 0.001). The most common barriers included confidentiality (59.9%), unsupportive parents (58.0%), and uncertainty about where to get care (52.9%).Conclusions: These findings provide a better understanding of the mental health care utilization and needs among TNB individuals in adolescence. Further research focused on ways to support TNB adolescents and how parents can support their TNB adolescents' mental health is warranted.","PeriodicalId":94256,"journal":{"name":"Transgender health","volume":"10 4","pages":"394-400"},"PeriodicalIF":1.8,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic and Anthropometric Changes and Adverse Effects in Finnish Adolescents Using Gender-Affirming Hormonal Treatment. 芬兰青少年使用性别确认激素治疗的代谢和人体测量变化和不良反应。

IF 1.8

Transgender health Pub Date : 2025-08-07 eCollection Date: 2025-09-01 DOI: 10.1089/trgh.2024.0012

Nico Vehmas, Elina Holopainen, Hanna Savolainen-Peltonen

{"title":"Metabolic and Anthropometric Changes and Adverse Effects in Finnish Adolescents Using Gender-Affirming Hormonal Treatment.","authors":"Nico Vehmas, Elina Holopainen, Hanna Savolainen-Peltonen","doi":"10.1089/trgh.2024.0012","DOIUrl":"https://doi.org/10.1089/trgh.2024.0012","url":null,"abstract":"Purpose: In this retrospective study our purpose was to assess whether hormone interventions for gender dysphoria pose additional somatic risks for adolescents. We examined changes in metabolic laboratory parameters, body mass index (BMI), and blood pressure (BP) and analyzed adverse effects during gender-affirming hormonal treatment (GAHT).Methods: We analyzed follow-up data on 119 transgender adolescents using GAHT at the adolescent gynecology clinic in Helsinki University Hospital, Finland from January 2010 to January 2022.Results: During the study period, 99 (83%) transgender males and 20 (17%) transgender females started GAHT. The median GAHT follow-up duration was 34.0 (interquartile range 17.2) months. Mean hemoglobin (HB) and hematocrit (HCT) levels increased by 16% (p < 0.001) during testosterone treatment, decreased by 10% (p < 0.01) during estrogen treatment, and plateaued after one year. During the initial follow-up, no clinically relevant changes were seen in glucose and lipid metabolism, BMI, or BP. Adverse effects leading to testosterone dose reduction were reported in 19% of transgender males and were less common when gonadotropin-releasing hormone analog was used in testosterone treatment initiation (11.1% vs. 27.8%, p = 0.04). Somatic adverse effects requiring hospitalization or permanent discontinuation of GAHT were not reported.Conclusion: The somatic changes observed in this study were typical for GAHT. No serious somatic adverse effects occurred. Regular measuring of HB and HCT in transgender males undergoing GAHT is warranted, but excessive monitoring of glucose and lipid metabolism, BMI, and BP during the initial follow-up period may not be necessary for somatically healthy adolescents.","PeriodicalId":94256,"journal":{"name":"Transgender health","volume":"10 4","pages":"306-315"},"PeriodicalIF":1.8,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12434160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145077062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Benefits of Gender-Affirming Voice and Communication Training for Young People. 为年轻人提供性别确认声音和沟通培训的好处。

IF 1.8

Transgender health Pub Date : 2025-08-07 eCollection Date: 2025-09-01 DOI: 10.1089/trgh.2024.0207

Brett R Myers, Catharine DeLong

{"title":"Benefits of Gender-Affirming Voice and Communication Training for Young People.","authors":"Brett R Myers, Catharine DeLong","doi":"10.1089/trgh.2024.0207","DOIUrl":"https://doi.org/10.1089/trgh.2024.0207","url":null,"abstract":"Purpose: Gender-affirming voice training is an important service for transgender and gender-diverse (TGD) individuals who wish to modify their voice to be more congruent with their gender identity. For decades, the research in this area has focused on adults, yet TGD young people also receive these services regularly. The purpose of this study was to analyze patient-reported outcomes in TGD young people who completed voice training.Methods: This study consisted of a retrospective chart review of 118 TGD individuals ages 11 to 23 years old who were seen at a university clinic between 2019 and 2024. We assessed voice outcomes with the Utah Gender Presentation Scale for Communication (U-GPS), the Trans Woman Voice Questionnaire (TWVQ), and acoustic measures. These data were compared before and after voice training.Results: Data were available for 68 clients who completed voice training. There were significant improvements in gender congruence by the end of treatment (t = 15.918; p < 0.001) with a median reduction of 32 points on the U-GPS. The trans female clients had significant improvements in voice-related quality of life (t = 12.072; p < 0.001) with a median reduction of 23 points on the TWVQ. Acoustic data show that speaking fundamental frequency (f0) was more aligned with clients' gender by the end of voice training.Conclusion: This article is the first to demonstrate the benefits of voice training for TGD young people. This population warrants special attention in the literature, and further research should evaluate specific treatment protocols and associated outcomes for young people.","PeriodicalId":94256,"journal":{"name":"Transgender health","volume":"10 4","pages":"364-374"},"PeriodicalIF":1.8,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12434159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145077067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Estrone/Estradiol Ratio and Levels in Transfeminine Individuals on Different Routes of Estradiol. 不同途径雌二醇的跨女性个体雌酮/雌二醇比值及水平比较。

IF 2.1

Transgender health Pub Date : 2025-06-05 eCollection Date: 2025-06-01 DOI: 10.1089/trgh.2023.0138

Navin M Kariyawasam, Tehmina Ahmad, Shohinee Sarma, Raymond Fung

{"title":"Comparison of Estrone/Estradiol Ratio and Levels in Transfeminine Individuals on Different Routes of Estradiol.","authors":"Navin M Kariyawasam, Tehmina Ahmad, Shohinee Sarma, Raymond Fung","doi":"10.1089/trgh.2023.0138","DOIUrl":"10.1089/trgh.2023.0138","url":null,"abstract":"Purpose: Estradiol for gender-affirming hormone therapy can be taken in different routes: oral, sublingual, transdermal patch or gel, and injectable estradiol. We aimed at comparing the estrone and estradiol ratios and levels achieved in each of these different routes of estradiol.Methods: We conducted a retrospective chart review of transfeminine individuals attending an endocrinology clinic in Toronto, Canada. Study participants were grouped according to the route of estradiol administration: oral, injectable, transdermal, and sublingual. Our primary outcome was the estrone/estradiol ratio (E1/E2). Our secondary outcomes were the estradiol and estrone levels in each of these four groups.Results: We included 286 patients. The oral estradiol group had the highest E1/E2 ratio (9.28), followed by the sublingual group (6.88). Both the transdermal and injectable groups had substantially lower E1/E2 ratios (2.22 and 0.84, respectively). We observed a large variability of the E1/E2 ratio in the oral and sublingual groups, whereas the transdermal and the injectable groups' ratios had much smaller standard deviation. The mean estradiol in the injectable group (1557 pmol/L, 424.1 pg/mL) was markedly higher than the estradiol levels observed in all other routes of estradiol.Conclusion: Our data demonstrate significantly different E1/E2 ratios in the four different routes of estradiol administration, with oral and sublingual routes having the highest E1/E2 ratios followed by transdermal and injectable routes.","PeriodicalId":94256,"journal":{"name":"Transgender health","volume":"10 3","pages":"261-268"},"PeriodicalIF":2.1,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144478355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Special Issue: Health Outcomes of Gender-Affirming Care Among Transgender and Gender Expansive Youth: Deadline for Manuscript Submission: September 17, 2024. 特刊：变性和性别扩展青少年中性别确认护理的健康结果：投稿截止日期：2024 年 9 月 17 日。

IF 1.8

Transgender health Pub Date : 2024-08-16 eCollection Date: 2024-08-01 DOI: 10.1089/trgh.2024.44968.cfp

David J Inwards-Breland

引用次数: 0

Letter to the Editor: Extending the Reach of Peer-Led Support Groups via Telehealth. 致编辑的信：通过远程医疗扩大同伴互助小组的覆盖范围。

IF 2.1

Transgender health Pub Date : 2024-06-17 eCollection Date: 2024-06-01 DOI: 10.1089/trgh.2022.0136

Moira A Kyweluk, Katie S Greeley, Jerrica Kirkley

引用次数: 0

Prescription Pain Reliever Misuse Among Transgender and Gender Diverse Adults. 变性和性别多元化成年人中滥用止痛药的情况。

IF 2.1

Transgender health Pub Date : 2024-01-31 eCollection Date: 2024-02-01 DOI: 10.1089/trgh.2022.0059

Leonardo Kattari, Haley Hill, Deirdre A Shires, Lucas R Prieto, Ishaan K Modi, Brayden A Misiolek, Shanna K Kattari

{"title":"Prescription Pain Reliever Misuse Among Transgender and Gender Diverse Adults.","authors":"Leonardo Kattari, Haley Hill, Deirdre A Shires, Lucas R Prieto, Ishaan K Modi, Brayden A Misiolek, Shanna K Kattari","doi":"10.1089/trgh.2022.0059","DOIUrl":"10.1089/trgh.2022.0059","url":null,"abstract":"Purpose: Little is known about the prevalence and risks associated with transgender and gender diverse (TGD) persons' misuse of prescription pain relievers (PPRs). This study explores the relationship between PPR misuse and various sociodemographic identities and experiences of discrimination in health care among TGD adults.Methods: TGD participants (n=595) were recruited in 2018 to participate in a cross-sectional statewide trans health survey through convenience sampling. Chi-square tests of independence and logistic regressions were conducted to explore associations between sociodemographics and experiences of discrimination among persons who had ever misused PPRs, or who had misused PPRs in the past year.Results: Sociodemographics such as gender identity (odds ratio [OR]=0.44, p=0.01), race/ethnicity (OR=0.14, p<0.001), and sexual orientation influence TGD individuals likeliness of misusing PPRs (OR=0.40, p<0.001). Notably, those who were ever diagnosed with anxiety had a higher likeliness of having lifetime PPR misuse compared with those who were never diagnosed (OR=2.05, p=0.05), and those reporting past-year discrimination within the mental health care setting because of their gender identity were more than twice as likely to report past-year misuse than those who reported not experiencing it (OR=2.43, p=0.004).Conclusion: Certain subpopulations of TGD individuals may be at elevated risk of PPR misuse. It is imperative to acknowledge the impact of multimarginalized identities as well as differences across various identities and experiences within the TGD community while working to address non-PPR misuse.","PeriodicalId":94256,"journal":{"name":"Transgender health","volume":"9 1","pages":"68-75"},"PeriodicalIF":2.1,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10835153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139682217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acknowledgment of Reviewers 2023. 鸣谢 2023 年审稿人。

Transgender health Pub Date : 2024-01-31 eCollection Date: 2024-02-01 DOI: 10.1089/trgh.2024.29003.ack

引用次数: 0

An Exploratory Comparison and Evaluation of Two Two-Step Measures to Identify Transgender People in Survey Datasets 探索性比较和评估在调查数据集中识别变性人的两种两步措施

Transgender health Pub Date : 2023-12-06 DOI: 10.1089/trgh.2023.0010

D. Felt, L. Beach, Florence Ashley, Gregory Phillips

引用次数: 0

Efficient Expansion of a Behavioral Survey to Assess Sex, Gender, and Behavioral Risk Among Transgender and Nonbinary Individuals: HMU! (HIV Prevention for Methamphetamine Users). 有效扩展行为调查以评估跨性别和非二元个体的性别、性别和行为风险：HMU！（为甲基苯丙胺使用者预防艾滋病毒）。

IF 2.1

Transgender health Pub Date : 2023-10-04 eCollection Date: 2023-10-01 DOI: 10.1089/trgh.2021.0082

Noah Frank, Vanessa M McMahan, Lauren R Violette, Aleks Martin, Sara N Glick, Joanne D Stekler

引用次数: 0